| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/04/2026 | ±3.1% | +3.6% | under-priced |
| 05/05/2026 | ±3.1% | -0.0% | over-priced |
| 11/03/2025 | ±1.8% | +14.8% | under-priced |
| 05/01/2025 | ±2.8% | +8.9% | under-priced |
| 10/31/2024 | ±2.0% | -9.8% | under-priced |
| 08/06/2024 | ±3.6% | +3.1% | over-priced |
| 05/01/2024 | ±2.6% | -5.0% | under-priced |
| 11/01/2023 | ±3.7% | -1.0% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $4.27 | $1.2B | $338M |
| Q1 FY2026 | $3.47 | $1.1B | $278M |
| Q4 FY2025 | $3.09 | $1.1B | $248M |
| Q3 FY2025 | $3.40 | $1.1B | $275M |
Idexx Laboratories Inc (IDXX) reports in 121 days, with the next report estimated for 01/11/2027. Across the last 8 reports, options priced an average ±2.8% earnings move while the stock actually moved 5.8% on average — the market has been roughly fair on IDXX's earnings risk. Fundamentals into the print: EPS up 0.0% year-over-year, revenue up 0.0%. QuantLogix's live 5-factor engine currently reads IDXX as a underweight at 26/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →